Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 432 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Primary endpoints: details revised at 1 of 7 entries
    • Eligibility criteria expanded, about 7 words
    • Study description expanded, about 20 words
  3. 16 versions Re-verified since Mar 19, 2026, no change to tracked fieldsv415-v430
  4. Study Status, Study Description, Arms and Interventions, Outcome Measures, Eligibilityv414
  5. 31 versions Re-verified since Apr 1, 2025, no change to tracked fieldsv383-v413
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI....
Trial Details
NCT Number NCT00026884
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer, Bladder Cancer
Related terms Kidney Neoplasms, Neoplasms, Neoplastic Syndromes, Hereditary, Urinary Bladder Neoplasms
Enrollment 5,950 participants
Start Date
Updated on ClinicalTrials.gov